Thus, inhibition of GABARAPL1 could potentially alter tumour growth by affecting intrinsic factors, for example, downstream signalling of EGFR, leading to decreased cell proliferation, resulting in decreased tumour growth. This evidence concerns the gene EGFR and neoplasm.